jeudi 2 mars 2017

Onco Actu du 2 mars 2017


2.11 Etiologie - Alimentation

Poor Adolescent and Early Adulthood Diet Associated With Increased Risk for Premenopausal Breast Cancer [AACR]

2.7 Etiologie - Obésité

Wide range of cancers now linked to being overweight [NHS Choices]

4. Dépistage, diagnostic et pronostic

Novel Calculator More Easily Identifies Patients Who Will Benefit From Neoadjuvant Chemoradiation [Roswell Park Cancer Institute]

Two migration proteins boost predictive value of pancreatic cancer biomarker [MD Anderson Cancer Center]

4.12 Biopsies liquides

Grail reels in $900M to bankroll large-scale cancer-screening trials [FierceBiotech]

Drugmakers, Amazon Back Grail’s Big Cancer Trials With $900M [Xconomy]

Bristol-Myers Squibb Expands Focus on Precision Medicine with Investment and Planned Collaboration with GRAIL on Blood-Based Cancer Screening [BMS]

GRAIL Closes Over $900 Million Initial Investment in Series B Financing to Develop Blood Tests to Detect Cancer Early [GRAIL]

5. Traitements

Increased survival with new treatment for aggressive form of childhood cancer [Karolinska Institutet]

Thwarting Deadly Diseases Before They Start: The New Science of Cancer Interception [Johnson & Johnson]

5.10 Traitements - Essais

Sanofi Launches Digital Clinical Trials to Improve Recruitment and Reduce Trial Times [Sanofi]

5.12.2 Immunothérapies - CAR-T

After Trial Deaths, Juno Pivots and Scraps Lead CAR-T Therapy [Xconomy]

Juno pulls the plug on a once-promising cancer treatment [STAT]

Months after another lethal setback, Juno finally opts to kill lead CAR-T [EndPoints]

Juno ends development of high-profile leukemia drug after deaths [Reuters]

5.2 Pharma

Celgene, Agios gain FDA speedy review for AML med enasidenib [FierceBiotech]

FDA Accepts New Drug Application and Grants Priority Review for Enasidenib in Relapsed or Refractory AML with an IDH2 Mutation [Celgene]

Phase III APHINITY Study Shows Genentech’s Perjeta® Regimen Helped People with an Aggressive Type of Early Breast Cancer Live Longer without their Disease Returning Compared to Herceptin® and Chemotherapy [Genentech]

Celgene, Agios beat a short path to an FDA decision on AML drug [EndPoints]

Roche says drug combo cuts breast cancer deaths in key trial [Reuters]

5.3.4 Traitements - AMM (FDA, EMA)

FDA Approves Nivolumab for Bladder Cancer [NCI]

5.4 Traitements - Economie

NICE shoots down Merck's Keytruda in first-line NSCLC—and the med won't be getting any CDF love, either [FiercePharma]

NICE says patients accessing more cancer drugs following price drops [NICE]

5.9 AACR

Welcome to the AACR Annual Meeting 2017 Online Itinerary Planner [AACR]

5.9.8 AACR - Pharma

ImmunoGen Announces Presentations at AACR Annual Meeting [ImmunoGen]

NewLink Genetics Announces Presentation of Two Abstracts at AACR [NewLink Genetics]

Bristol-Myers Squibb to Present Data That Advances Understanding of Effects of Immuno-Oncology Therapies on Cancer Biology and Patient Outcomes at AACR 2017 [BMS]

6.1 Observation

Colorectal Cancer Statistics, 2017 [ACS]

6.10.1 Politiques (USA)

Would Trump's FDA Deregulation Create An Age Of Miracles? Don't Bet On It [Forbes]

6.11 Patients

People who are dying should be asked about their spiritual beliefs, says NICE [NICE]

6.3 Associations/Fondations

Patient advocacy groups have close ties with industry, but some lack transparency [STAT]

More Than 80 Percent of Patient Groups Accept Drug Industry Funds, Study Shows [NY Times]